Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mindfulness-Based Stress Reduction for Gulf War Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT01267045
First received: December 23, 2010
Last updated: December 15, 2014
Last verified: December 2014
Results First Received: November 4, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Condition: Persian Gulf Syndrome
Intervention: Behavioral: Mindfulness-based stress reduction

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm 1

Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction.

Mindfulness-based stress reduction: A common clinical method of teaching mindfulness is a class series called "mindfulness-based stress reduction" (MBSR), which is available at over 250 hospitals nationwide. MBSR teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.

Arm 2 Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)

Participant Flow for 2 periods

Period 1:   2-month Outcomes
    Arm 1     Arm 2  
STARTED     26     29  
COMPLETED     22     26  
NOT COMPLETED     4     3  

Period 2:   6-month Outcome
    Arm 1     Arm 2  
STARTED     22     26  
COMPLETED     22     23  
NOT COMPLETED     0     3  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Arm 1

Participants in this arm undergo the mindfulness training intervention through taking part in Mindfulness-Based Stress Reduction.

Mindfulness-based stress reduction: A common clinical method of teaching mindfulness is a standardized class called "mindfulness-based stress reduction" (MBSR), which is available at over 250 hospitals nationwide. MBSR teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.

Arm 2 Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
Total Total of all reporting groups

Baseline Measures
    Arm 1     Arm 2     Total  
Number of Participants  
[units: participants]
  26     29     55  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     25     29     54  
>=65 years     1     0     1  
Age  
[units: years]
Mean ± Standard Deviation
  51.3  ± 6.8     48.6  ± 7.4     49.9  ± 6.0  
Gender  
[units: participants]
     
Female     3     5     8  
Male     23     24     47  
Race (NIH/OMB)  
[units: participants]
     
American Indian or Alaska Native     0     1     1  
Asian     1     2     3  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     2     8     10  
White     17     17     34  
More than one race     0     0     0  
Unknown or Not Reported     6     1     7  
Region of Enrollment  
[units: participants]
     
United States     26     29     55  
McGill Pain Questionnaire score [1]
[units: units on a scale]
Mean ± Standard Deviation
  75  ± 32.5     81.2  ± 41.9     77.1  ± 31.3  
Multidimensional Fatigue Inventory [2]
[units: units on a scale]
Mean ± Standard Deviation
     
General Fatigue     16.0  ± 2.8     15.5  ± 3.2     15.8  ± 3.0  
Physical Fatigue     14.4  ± 2.7     15.3  ± 2.9     14.9  ± 2.8  
Reduced Activity     14.9  ± 4.1     14.3  ± 3.8     14.6  ± 3.9  
Reduced Motivation     11.5  ± 2.4     11.6  ± 2.4     11.5  ± 2.4  
Mental Fatigue     15.5  ± 3.6     15.6  ± 3.2     15.5  ± 3.3  
Cognitive Failures Questionnaire [3]
[units: units on a scale]
Mean ± Standard Deviation
  59.6  ± 16.5     58.3  ± 18.7     58.9  ± 17.5  
PTSD Symptom Scale Interview  
[units: units on a scale]
Mean ± Standard Deviation
  29  ± 11.2     26.2  ± 10.6     27.5  ± 10.9  
Medication Use at Baseline [4]
[units: participants]
     
Opiate     14     5     19  
Antidepressant     13     14     27  
Benzodiazepine     4     4     8  
Amphetamine     2     3     5  
Musculoskeletal Pain  
[units: participants]
     
Current musculoskeletal pain diagnosis     20     27     47  
No musculoskeletal pain diagnosis     6     2     8  
Neurologic Pain  
[units: participants]
     
Current neurologic pain diagnosis     14     15     29  
No neurologic pain diagnosis     12     14     26  
Gastrointestinal Condition  
[units: participants]
     
Current GI condition diagnosis     10     19     29  
No GI condition diagnosis     16     10     26  
Respiratory Conditions  
[units: participants]
     
Current respiratory condition diagnosis     10     12     22  
No respiratory condition diagnosis     16     17     33  
[1] The Short-Form McGill Pain Questionnaire is a self-report 22-item measure that assesses various types of pain on a scale of 0 (none) to 10 (worst possible) experienced during the past week.
[2] The Multidimensional Fatigue Inventory is a 20-item self-report measure of various types of fatigue. Each item is a statement, and the subject indicates how much, on a scale of 1 (yes, that is true) to 5 (no, that is not true), he or she agrees with the statement (e.g. "I feel very active.")
[3] The Cognitive Failure Questionnaire is a 25-item self-report measure of cognitive difficulty during daily living in the past six months. Each item is a question indicating a situation involving a type of cognitive failure (e.g. “Do you find you forget why you went from one part of the house to another?”), and the subject indicates how often that happens to them, on a scale of 0 (never) to 4 (very often).
[4] This is a summary of the prevalence of medication use among the study participants. Since each participant could endorse anywhere from none of these medications to all four types of medication, the total number is unlikely to add up to the exact number of participants.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Short-form McGill Pain Questionnaire   [ Time Frame: 2 months ]

2.  Primary:   The Short-Form McGill Pain Questionnaire   [ Time Frame: 8 months ]

3.  Primary:   Multidimensional Fatigue Inventory - General Fatigue   [ Time Frame: 2 months ]

4.  Primary:   Multidimensional Fatigue Inventory - General Fatigue   [ Time Frame: 8 months ]

5.  Primary:   Cognitive Failures Questionnaire   [ Time Frame: 2 months ]

6.  Primary:   Cognitive Failures Questionnaire   [ Time Frame: 8 months ]

7.  Secondary:   Patient Health Questionnaire (PHQ-9)   [ Time Frame: 2 months ]

8.  Secondary:   Patient Health Questionnaire (PHQ-9)   [ Time Frame: 8 months ]

9.  Secondary:   PTSD Symptom Severity Interview (PSSI)   [ Time Frame: 2 months ]

10.  Secondary:   PTSD Symptom Severity Interview (PSSI)   [ Time Frame: 8 months ]

11.  Secondary:   PROMIS Fatigue   [ Time Frame: 2 months ]

12.  Secondary:   PROMIS Fatigue   [ Time Frame: 8 months ]

13.  Secondary:   Five Facet Mindfulness Questionnaire   [ Time Frame: 2 months ]

14.  Secondary:   Five Facet Mindfulness Questionnaire   [ Time Frame: 8 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: David J. Kearney, MD
Organization: VA Puget Sound Health Care System
phone: 206-277-1445
e-mail: David.Kearney@VA.gov


No publications provided


Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT01267045     History of Changes
Other Study ID Numbers: SPLD-008-10S
Study First Received: December 23, 2010
Results First Received: November 4, 2014
Last Updated: December 15, 2014
Health Authority: United States: Federal Government